• Abera Bioscience posted a loss after financial items of SEK 5.56 million in Q2 2026, widening from SEK 833,000 a year earlier.
• Loss per share widened to SEK 0.27; net sales were nil.
• Other operating income fell to SEK 1.56 million from SEK 4.3 million in the year-ago quarter.
• Equity ratio rose 24 percentage points to 80%.
• GMP production of Ab-01.12 clinical trial material was completed; a Phase I application was submitted in the Netherlands after quarter-end.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abera Bioscience AB published the original content used to generate this news brief via Cision (Ref. ID: 202608200150BITN____UKPR__SV_20260820-BIT-9941-0) on August 20, 2026, and is solely responsible for the information contained therein.